Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Holly Graft go back to the drawing board?

This article was originally published in The Gray Sheet

Executive Summary

CABG Medical's drug-eluting artificial coronary artery bypass graft might need to be redesigned following an initial 35-patient arm of a clinical trial that failed to "meet the standards necessary to obtain regulatory product approvals," according to CEO Manny Villafana. In the study, in which patients were implanted with the graft and treated with aspirin and Plavix, 12 grafts occluded and became non-functional. The next enrollment arm will follow five graft-implanted patients, treated with warfarin and aspirin, for 60 days. If results are positive, a total of 30 patients will be followed for six months. A pivotal trial would still be necessary for FDA approval...
Advertisement

Related Content

Occlusions Prompt CABG Medical To Halt Holly Graft Trial
Advertisement
UsernamePublicRestriction

Register

MT022934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel